CClinicalTrials.gg
CompletedNCT02014220Updated Dec 18, 2013

The Food Intake, Satiety and Blood Glucose After Ingestion of Potato Chips Produced From Three Potato Cultivars

An interventional study of dietary treatment in Obesity, Overweight and Diabetes, sponsored by University of Toronto. Completed at 1 site in Canada. Open to male participants aged 18 Years to 35 Years. Per ClinicalTrials.gov, last updated 2013-12-18.

Sponsored by University of Toronto · Not applicable, Interventional, and Prevention

Phase
Not applicable
Study type
Interventional
Ages
18 Years to 35 Years
Sex
Male
01

Study summary

Potato is one of the world's most popular foods and is widely accepted as a staple food. The objective of this study is to determine the effect of consuming potato chips from different cultivars on blood glucose, subjective appetite and food intake. It is hypothesized that the chips produced from various potato cultivars will differ in their effect on blood glucose, satiety and food intake.

02

Conditions studied

  • Obesity
  • Overweight
  • Diabetes
  • Metabolic Syndrome
03

In context

Overweight

3,671 studies on the registry are indexed under Overweight; 850 are open to participants now.

Browse Overweight studies →

Lead sponsor

University of Toronto is the lead sponsor of 397 studies on the registry; 59 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 35 Years
Sexes eligible
Male
Accepts healthy volunteers
No

Inclusion criteria

  • Healthy men with a body mass index (kg/m2) of 20-24.9

Exclusion criteria

Exclusion Criteria:

  • smocking, medication, breakfast skipping, restrained eating
05

Study design

Phase
Not applicable
Primary purpose
Prevention

Study arms

  • Experimental
    Atlantic Western chips

    deep fried potato chips

    Other: dietary treatment

  • Experimental
    Dakota Pearl chips

    deep fried potato chips

    Other: dietary treatment

  • Experimental
    Andover Ontario chips

    deep fried potato chips

    Other: dietary treatment

  • Experimental
    white bread with margarine

    energy control

    Other: dietary treatment

  • Experimental
    white bread

    control

    Other: dietary treatment

Interventions

  • Otherdietary treatment
06

What researchers measure

Primary outcomes

  1. blood glucose

    Glycaemic response will be measured before the treatment (baseline) and at 15, 30, 45, 60, 90 and 120 min after the treatment. The glucose concentration will be measured in capillary blood using portable glucose meter.

    Time frame: 120 min

Secondary outcomes

  1. food intake

    Ad libidum food intake will be measure at 120 min using test pizza meal. The amount of consumed test meal (g) will be converted to the energy (kcal).

    Time frame: 120 min

Other outcomes

  1. satiety

    Subjective appetite will be measured with visual analogue scales at 0 min immediately before the treatment (baseline) and at 15, 30, 45, 60, 90 and 120 min after the treatment.

    Time frame: 120 min

07

Study locations

1 site
  • Department of Nutritional Sciences
    Toronto, Ontario M5S 3E2, Canada
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Dec 18, 2013, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT02014220
Lead sponsor
University of Toronto
Responsible party
G. Harvey Anderson (Professor, University of Toronto) — Principal investigator
First posted
Dec 18, 2013
Primary completion
Dec 2008
Last update
Dec 18, 2013
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2013. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion